Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.51 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12093157 | 0.86 | FFAR4 (0.41) | FFAR4MLNRPTGS1PTGS2MTNR1B | |
| SCHEMBL31345444 | 0.83 | FFAR4 (0.42) | FFAR4MLNRPTGS1PTGS2MTNR1B | |
| SCHEMBL20972028 | 0.79 | FFAR4 (0.36) | FFAR4MLNRPTGS1PTGS2EPHX2 | |
| SCHEMBL23434787 | 0.79 | PTGS1 (0.44) | FFAR4MLNRPTGS1PTGS2MTNR1B | |
| SCHEMBL24716435 | 0.77 | PTGS1 (0.46) | FFAR4PTGS1PTGS2GPR119EPHX2 | |
| SCHEMBL6565551 | 0.77 | PTGS1 (0.48) | FFAR4PTGS1PTGS2EPHX2ALDH1A1 | |
| SCHEMBL16950678 | 0.77 | NQO1 (0.48) | FFAR4ALDH1A1TSHRFFAR1 | |
| SCHEMBL697670 | 0.74 | CHRM2 (0.50) | MTNR1BALDH1A1 | |
| SCHEMBL16483442 | 0.73 | HTR2C (0.46) | FFAR4PTGS1PTGS2GPR119EPHX2 | |
| SCHEMBL15057385 | 0.73 | FFAR4 (0.42) | FFAR4PTGS1PTGS2GPR119EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739669-A1 | SODIUM CHANNEL BLOCKERS | Novartis AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20250034108-A1 | SODIUM CHANNEL BLOCKERS | NOVARTIS AG (CH) | 2025-01-30 | — | — | US | disclosed |
| WO-2025011450-A1 | SODIUM CHANNEL BLOCKERS | NOVARTIS AG (CH) | 2025-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034108-A1 | SODIUM CHANNEL BLOCKERS | SCN5A, SCN2B, SCN1B | FFAR4 2044/4885MLNR 1182/4885PTGS1 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.